CJC-1295 Without DAC CAS:863288-34-0

CJC-1295 Without DAC Descrption:

CJC-1295 is a Long acting GHRH analog hormone-releasing hormone (GHRH), also known as hormone-releasing factor (GRF or GHRF) or somatocrinin, is a 44-amino acid peptide hormone produced in the hypothalamus by the arcuate nucleus. GHRH stimulates hormone (GH) secretion from the pituitary. GHRH is released in a pulsatile manner, stimulating pulsatile release of GH respectively.

CJC-1295 Without DAC Application:

Modified GRF 1-29 is also known as Mod GRF 1-29, but even more commonly known as CJC-1295 without DAC. It is a protein that is 29 amino acids long and it is a GHRH analogue. CJC-1295 without DAC acts on receptors at the pituitary gland to stimulate the release of Human Growth Hormone.

CJC-1295 Without DAC Dosage:

CJC-1925 is a sterile, non-pyrogenic, white lyophilized powder intended for subcutaneous or intramuscular injection, after reconstitution with sterile Water for Injection. CJC-1295 can be injected subcutaneously with an insulin syringe. Dose per injection: 2mg. Injections per vial: 1 X 2mg dosages Amount to Inject: If you have used 0.5ml of water for mixing then a 2mg dosage = 0.50ml (or 50 units on Insulin Syringe). If you have used 1ml of water then a 2mg dosage = 1ml (or 100 units). Sample Injection Frequency: 2mg injected once per week (due to its long half-life).

Research study participants for often cycle doses 2-3 times per day (ex: before breakfast, before bed, and after exertion) for a period up to several weeks. These cycles, or pulses are meant to closely mimic natural secretion of GH. For CJC 1295, dosing is less frequent since the half-life with DAC is up to 8 days. Therefore, the cycle for CJC 1295 with DAC calls for once weekly injections that result in an overall increase of secretion of GH. At this point, research does not show any significant advantage for one cycle over the other, so it is a matter of personal preference.